Hualing Pharmaceuticals: After obtaining approval in Hong Kong, Dapagliflozin will be listed in Macau and Southeast Asia.

Today, reporters learned from Hualing Pharmaceuticals that the company's independently developed global first glucokinase activator Degletin has been approved for listing by the Department of Health of the Hong Kong Special Administrative Region for the treatment of type 2 diabetes in adults. This product is also the first innovative drug for chronic metabolic diseases and the first approved Chinese original innovative drug under the "1+" drug regulation mechanism in Hong Kong. Hualing Pharmaceuticals told reporters that the company, with Hong Kong as the hub, has taken a key step towards officially entering Southeast Asia and global markets from China, and will continue to promote the listing process of Degletin in the Macao Special Administrative Region of China, achieving its comprehensive landing in the Guangdong-Hong Kong-Macao Greater Bay Area.